{"schema_version":"secwatch.filing_event.v1","accession":"0001370053-24-000010","form_type":"8-K","ticker":"ANAB","cik":"0001370053","company_name":"ANAPTYSBIO, INC","filed_at":"2024-03-11T23:59:59+00:00","discovered_at":"2026-05-14T18:03:23.971473+00:00","generated_at":"2026-06-04T23:43:15.053073+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"AnaptysBio reports Q4 2023 net loss of $42.2M, cash $417.9M; pipeline on track","bullets":["Q4 net loss $42.2M ($1.59 per share); full-year net loss $163.6M ($6.08 per share).","Cash & investments $417.9M at Dec 31, 2023 (down from $584.2M year-end 2022); runway through 2026.","R&D spend $33.5M in Q4, up 43% YoY, driven by rosnilimab, ANB032, and ANB033 manufacturing.","ANB032 Phase 2b atopic dermatitis top-line data expected by year-end 2024; rosnilimab RA data mid-2025, UC data H1 2026.","IND filings for ANB033 (anti-CD122) in Q2 2024 and ANB101 (BDCA2) in H2 2024; ANB101 licensed for $7M upfront."],"urls":{"canonical":"https://secwatch.observer/filing/0001370053-24-000010","json":"https://secwatch.observer/filing/0001370053-24-000010.json","markdown":"https://secwatch.observer/filing/0001370053-24-000010.md","text":"https://secwatch.observer/filing/0001370053-24-000010.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1370053/000137005324000010/0001370053-24-000010-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1370053/000137005324000010/anab-20240311.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-04T23:43:15.053073+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"0ce283c339067014406dcc4d8b37151f7f8b6a88","claim":"ANAPTYSBIO, INC reported financial results for the fourth quarter and year ended December 31, 2023.","evidence_excerpt":"On March 11, 2024, AnaptysBio, Inc. (“AnaptysBio”) issued a press release announcing its financial results for the three months and year ended December 31, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1370053/000137005324000010/0001370053-24-000010-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fourth quarter and year ended December 31, 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}